Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery

Award recognizes collaboration and innovation in design and manufacture of advanced technology to support vaccine clinical research and new drug development.

May 29, 2015, 07:28 ET from Invetech

SAN DIEGO and BOSTON, May 29, 2015 /PRNewswire/ -- Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development.  The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.

Nanopatch™ is a next-generation drug delivery platform that consists of an array of thousands of coated microprojections able to perforate the dermal layer to deliver vaccine into the outer layers of the skin.  Vaccine delivery using Nanopatch has the potential to offer significant advantages over traditional injections, including needle-free drug delivery, reduced pain, no need for refrigerated supply chain,  improved vaccine effectiveness and low cost of manufacture.  A key consideration in product development is the ability to apply vaccine to the microprojections effectively.  In this collaboration, design and engineering teams at Invetech and Vaxxas worked together to develop a unique drying protocol able to provide essential levels of precision and control in manufacturing and product replication.  This, in turn, supports the potential use of Nanopatch in a range of vaccine clinical research programs.

"Our collaboration with Vaxxas is a great demonstration of how Invetech can complement the important work of emerging leaders in medical technology with additional insight and know-how to address very specific and complex challenges," said Richard Grant, global vice president at Invetech.  "We are all very pleased that the Nanopatch Jet Coating Instrument, which represents an important milestone in drug delivery innovation, has been named the recipient of a 2015 Good Design Award."

The collaboration between Invetech and Vaxxas resulted in development of an instrument that enables controlled coating of the micro-projections with drug compounds followed by specific drying protocols based on use of a unique gas jet technology.  Usability was a key consideration throughout the development process, targeting a platform that is easy to use, maintain and clean.  With these advantages, manufacturers are better able to achieve target goals in terms of precision and product replication necessary to advance vaccines to clinical stage research.

"Our goal with the Nanopatch has been to develop a technology that enables safer and more efficient vaccination versus administration via needle and syringe.  The Nanopatch has the potential to provide a better patient experience, with better overall economics because there is no need to maintain costly cold-chain.  Of course, development of an advanced technology platform like this presented some challenges," said Dr. Angus Forster, Vaxxas' chief development and operations officer.  "With our collaboration with Invetech, we brought together the range of expertise and insight to identify a new method to apply drug to microprojections that represents a major advance in our ability to deliver vaccines to patients."

About the Good Design Awards
Managed by Good Design Australia, the program proudly promotes the very best in design, innovation and creativity at a national and international level. The awards showcase superior examples of good design across a broad range of industries and design discipline. Entrants this year included such companies as Audi, Philips, Agilent and Braun.

About Vaxxas
Vaxxas is a venture capital funded technology start-up biotechnology company focused on enhancing the performance of existing and next-generation vaccines through its proprietary Nanopatch™ platform, a game-changing micro needle technology.   Vaxxas plans to apply its patented needle-free vaccination technology against major diseases, such as influenza, polio, bacterial infections, and cancer. 

About Invetech
Invetech has been creating breakthrough products and custom automation systems for more than 30 years. With experience drawn from more than 5,000 projects globally, Invetech partners with global leaders in industry to deliver product design and development, contract manufacturing, and custom automation services. The company has experience in a broad range of market sectors including cell therapy production automation systems, laboratory diagnostics, point of care diagnostics, life sciences, industrial and consumer products. 

Media Contact:

Bill Berry
Berry & Company Public Relations
bberry@berrypr.co,
212.253.8881

 

 

 

Photo - http://photos.prnewswire.com/prnh/20150528/219063

Photo - http://photos.prnewswire.com/prnh/20150528/219064

Logo - http://photos.prnewswire.com/prnh/20150528/219062LOGO

Logo - http://photos.prnewswire.com/prnh/20120809/MM55531LOGO

 

SOURCE Invetech



RELATED LINKS

http://www.invetech.com.au